Pages that link to "Q38005622"
Jump to navigation
Jump to search
The following pages link to Clinical development of novel therapeutics for castration-resistant prostate cancer: historic challenges and recent successes (Q38005622):
Displaying 20 items.
- Molecular landscape of prostate cancer: implications for current clinical trials (Q26799585) (← links)
- Clinical pharmacology and regulatory consequences of GnRH analogues in prostate cancer (Q34104391) (← links)
- Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras (Q36528402) (← links)
- Jungermannenone A and B induce ROS- and cell cycle-dependent apoptosis in prostate cancer cells in vitro (Q37112305) (← links)
- Targeting the adrenal gland in castration-resistant prostate cancer: a case for orteronel, a selective CYP-17 17,20-lyase inhibitor (Q38078285) (← links)
- GSTT1 and GSTM1 polymorphisms and prostate cancer risk in Asians: a systematic review and meta-analysis (Q38118611) (← links)
- Cell mates: paracrine and stromal targets for prostate cancer therapy. (Q38121792) (← links)
- Enzalutamide (Xtandi) for patients with metastatic, resistant prostate cancer (Q38181433) (← links)
- Targeting the relaxin hormonal pathway in prostate cancer. (Q38231840) (← links)
- The Rationale for Optimal Combination Therapy With Sipuleucel-T for Patients With Castration-resistant Prostate Cancer. (Q38261921) (← links)
- Docetaxel in combination with octreotide shows synergistic apoptotic effect by increasing SSTR2 and SSTR5 expression levels in prostate and breast cancer cell lines (Q38880901) (← links)
- Over-expression of lipocalin 2 promotes cell migration and invasion through activating ERK signaling to increase SLUG expression in prostate cancer (Q38904753) (← links)
- Dissecting major signaling pathways in prostate cancer development and progression: Mechanisms and novel therapeutic targets (Q38915711) (← links)
- mTOR regulate EMT through RhoA and Rac1 pathway in prostate cancer (Q38973649) (← links)
- Accumulation of trans-1-amino-3-[(18)F]fluorocyclobutanecarboxylic acid in prostate cancer due to androgen-induced expression of amino acid transporters (Q38983205) (← links)
- Identification of mutations, gene expression changes and fusion transcripts by whole transcriptome RNAseq in docetaxel resistant prostate cancer cells (Q39206549) (← links)
- Induction of Neuroendocrine Differentiation in Prostate Cancer Cells by Dovitinib (TKI-258) and its Therapeutic Implications (Q42108610) (← links)
- Small molecule activators of protein phosphatase 2A for the treatment of castration-resistant prostate cancer (Q50091777) (← links)
- CXCL1-LCN2 paracrine axis promotes progression of prostate cancer via the Src activation and epithelial-mesenchymal transition (Q89998130) (← links)
- Deubiquitinating enzyme USP33 restrains docetaxel-induced apoptosis via stabilising the phosphatase DUSP1 in prostate cancer (Q92133050) (← links)